Skip to main content

PULSE BIOSCIENCES INC

For the period ended Jun 30, 2024. Filed Aug 19, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 19, 2024

PLSE$58.17+9.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

PAGE No.
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited):3
Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 20233
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three- and Six-Month Periods Ended June 30, 2024 and 20234
Condensed Consolidated Statements of Cash Flows for the Six-Month Periods Ended June 30, 2024 and 20235
Condensed Consolidated Statements of Stockholders’ Equity for the Three- and Six-Month Periods Ended June 30, 2024 and 20236
Notes to Condensed Consolidated Financial Statements7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations18
Item 3. Quantitative and Qualitative Disclosures About Market Risk25
Item 4. Controls and Procedures25
PART II. OTHER INFORMATION
Item 1. Legal Proceedings26
Item 1A. Risk Factors26
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds48
Item 3. Default Upon Senior Securities48
Item 4. Mine Safety Disclosures48
Item 5. Other Information48
Item 6. Exhibits48
Signatures49

“Pulse Biosciences,” the Pulse logos and other trademarks or service marks that we use in connection with the operation of our business appearing in this quarterly report on Form 10-Q (this "Quarterly Report"), including CellFX, CellFX CloudConnect, CellFX Marketplace, Nano-pulse Stimulation, nsPFA, nano-PFA, CellFX nsPFA, and NPS, are the property of Pulse Biosciences, Inc. Solely for your convenience, some of our trademarks and trade names referred to in this Quarterly Report are listed without the ® and TM symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks and trade names. Also, this Quarterly Report may contain additional trade names, trademarks or service marks of others, which are the property of their respective owners. We do not intend our use or display of any other company’s trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any of these other companies.

Unless expressly indicated or the context requires otherwise, the terms “Pulse,” “Company,” “we,” “us,” and “our,” in this document refer to Pulse Biosciences, Inc., a Delaware corporation, and, where appropriate, its wholly owned subsidiaries.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.